News

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.
There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.
Signing into law the other criminal justice bill, named the Law and Order Act, Stein praised the effort by lawmakers to ...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health was upgraded to the Zacks Rank #1 list on July 9, 2025. The Zacks Rank is a unique stock-rating model that helps you take advantage of earnings estimate revision trends and provides a way ...
The most important philosophy we have of AI is that AI will never make decisions. Period. So AI would help us collect the ...
CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?
Health insurance companies, including CVS Caremark, are altering coverage for GLP-1 weight loss medications like Zepbound, ...
A customer who said she would be “heartbroken” if a community day centre closed has made her own personal bid to keep it ...